Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. Sandmann T, et al. Among authors: bourgon r. J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124478 Free PMC article.
Reply to T.J. Kruser et al.
Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T. Chinot OL, et al. Among authors: bourgon r. J Clin Oncol. 2016 Apr 10;34(11):1282-3. doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884575 No abstract available.
Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.
Daemen A, Udyavar AR, Sandmann T, Li C, Bosch LJW, O'Gorman W, Li Y, Au-Yeung A, Takahashi C, Kabbarah O, Bourgon R, Hegde P, Bais C, Das Thakur M. Daemen A, et al. Among authors: bourgon r. PLoS One. 2021 Dec 31;16(12):e0262198. doi: 10.1371/journal.pone.0262198. eCollection 2021. PLoS One. 2021. PMID: 34972191 Free PMC article. Clinical Trial.
gCMAP: user-friendly connectivity mapping with R.
Sandmann T, Kummerfeld SK, Gentleman R, Bourgon R. Sandmann T, et al. Among authors: bourgon r. Bioinformatics. 2014 Jan 1;30(1):127-8. doi: 10.1093/bioinformatics/btt592. Epub 2013 Oct 15. Bioinformatics. 2014. PMID: 24132929
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, Kim E, Zhang L, Farinha P, Gascoyne RD, Munoz FJ, Martelli M, Mottok A, Salles GA, Sehn LH, Seymour JF, Trnĕný M, Oestergaard MZ, Mundt KE, Vitolo U. Punnoose E, et al. Among authors: bourgon r. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):267-278.e10. doi: 10.1016/j.clml.2020.11.004. Epub 2020 Nov 10. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33303421 Free article.
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer.
Desbois M, Udyavar AR, Ryner L, Kozlowski C, Guan Y, Dürrbaum M, Lu S, Fortin JP, Koeppen H, Ziai J, Chang CW, Keerthivasan S, Plante M, Bourgon R, Bais C, Hegde P, Daemen A, Turley S, Wang Y. Desbois M, et al. Among authors: bourgon r. Nat Commun. 2020 Nov 4;11(1):5583. doi: 10.1038/s41467-020-19408-2. Nat Commun. 2020. PMID: 33149148 Free PMC article.
High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
Guan Y, Mayba O, Sandmann T, Lu S, Choi Y, Darbonne WC, Leveque V, Ryner L, Humke E, Tam NWR, Sujathasarma S, Cheung A, Bourgon R, Lackner MR, Wang Y. Guan Y, et al. Among authors: bourgon r. J Mol Diagn. 2017 Nov;19(6):921-932. doi: 10.1016/j.jmoldx.2017.08.001. Epub 2017 Sep 1. J Mol Diagn. 2017. PMID: 28867605 Free article.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Balar AV, et al. Among authors: bourgon r. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Lancet. 2017. PMID: 27939400 Free PMC article. Clinical Trial.
56 results